Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35895318.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1710.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radioactive iodine (RAI) treatment is an effective treatment for differentiated thyroid cancer (DTC); however, many patients are refractory. Using targeted drugs to reinduce RAI sensitivity ("redifferentiation therapy") has long been sought after as the holy grail in endocrine oncology. See related article by Weber et al., p. 4194.
Medical subject headings
- Adenocarcinoma
- Thyroid Neoplasms